Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
StemRIM Inc. ( (JP:4599) ) has issued an update.
StemRIM Inc. has announced the upcoming registration of a medical use patent for Redasemtide, its flagship regeneration-inducing drug candidate, specifically for treating fatty liver and non-alcoholic steatohepatitis (NASH) in Japan. With no existing drug treatments for these rising lifestyle-related conditions, this move could position StemRIM as a leader in addressing unmet medical needs while bolstering its market reputation within regenerative medicine.
More about StemRIM Inc.
StemRIM Inc. is a biotechnology venture originating from Osaka University, focused on developing a novel approach called ‘Regeneration-Inducing MedicineTM.’ This method aims to achieve regenerative therapy effects by mobilizing stem cells within the body to repair and regenerate damaged tissues without using living cells or tissues. The company targets various diseases, including chronic liver disease, cardiomyopathy, spinal cord injury, and others, through its innovative therapies.
Average Trading Volume: 110,021
Technical Sentiment Signal: Sell
Current Market Cap: Yen15.86B
For a thorough assessment of 4599 stock, go to TipRanks’ Stock Analysis page.